Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
This study has been completed.
Study NCT00432861   Information provided by Digestive Care, Inc.
First Received: February 7, 2007   Last Updated: August 29, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cystic Fibrosis
Pancreatic Insufficiency
Additional conditions recognized in this trial
Exocrine Pancreatic Insufficiency
Fibrosis
More general conditions related to this trial
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Interventions listed in this trial
PANCRECARB® (pancrelipase)
Placebo
Additional drug interventions recognized in this trial
Pancrelipase
More general drug interventions related to this trial
Gastrointestinal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Digestive Care, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services